BenchSci Company
BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery. BenchSci's vision is to bring medicine to patients 50% faster by 2025. The company empowers scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology accelerates science at 15 top 20 pharmaceutical companies and over 4,300 leading research centers worldwide. BenchSci is a CIX Top 10 Growth company, certified Great Place to Work, and top-ranked company on Glassdoor.
Investors
.jpg)
.png)
Technology:
Artificial Intelligence, Biotechnology, Life Science, Machine Learning, Pharmaceutical
Industry:
Early Drug Development
Headquarters:
Toronto, Ontario, Canada
Founded Date:
2015-01-01
Employees Number:
101-250
Funding Status:
Late Stage Venture
Investors Number:
14
Total Funding:
94533057
Estimated Revenue:
Less than $1M
Last Funding Date:
2022-01-24
Last Funding Type:
Series C
Register and Claim Ownership